ÂÜÀòÂÒÂ×

Dr. Broder has extensive experience as a scientist, oncologist, immunologist, and medical researcher. He is the former Director of the National Cancer Institute where he oversaw the development of numerous anti-cancer therapeutic agents and helped launch a number of large-scale clinical trials related to the prevention, diagnosis, and treatment of cancer and inaugurated the highly successful SPORE Program. His laboratory interests have included antiretroviral therapy, the relationship between immunodeficiency disorders and cancer, the human genome, and the proteomics of cancer cells. In particular, his laboratory was responsible for developing the first 3 agents approved by FDA specifically to treat the AIDS virus (Retrovir® (AZT), Videx® (ddI), and HIVID® (ddC)). After his tenure at the NCI, Dr. Broder served as Senior Vice President, Research and Development and Chief Scientific Officer at IVAX Corporation (now Teva Pharmaceuticals), as Executive Vice President for Medical Affairs and Chief Medical Officer at Celera Corporation and as Senior Vice President, Health Sector, Intrexon Corp. He currently serves as a member of the Board of Directors of Sensei Biotherapeutics and Geneos Therapeutics and sits on numerous scientific advisory boards. Dr. Broder is the author or co-author of over 340 scientific publications, and is an inventor on many patents. He has received numerous awards related to his research in cancer and AIDS and was elected to the National Academy of Medicine. He graduated from the University of Michigan Medical School, and did an internship and residency in Internal Medicine at Stanford and subspecialty training in medical oncology at the National Cancer Institute.